Breast Cancer

Diagnostics company updates NMP66 protein program for breast cancer detection

Published in Gene Therapy Weekly, June 23rd, 2005

Matritech (MZT), a developer of protein-based diagnostic products for the early detection of cancer, provided an update on preliminary results of pre-clinical tests in its NMP66 program for breast cancer detection.

Researchers analyzed 298 prospectively collected, blinded serum samples, using experimental versions of a colorimetric sandwich immunoassay and qualitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect the NMP66 protein complex in the blood of women with breast cancer. Serum samples were from women with a range of stages of breast cancer, biopsy confirmed benign breast diseases, and those with no mammographic evidence of breast...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-06-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry